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WOMEN'S HEALTH RESEARCH IN CANADA:
FEMINIST CHANGE IN A MURKY ZONE OF LAW,
MEDICINE AND POLITICS

ABSTRACT

The general aim of this paper is to explore the relationship between
law and the potential for social change in the context of women's health.
More specifically, I will critically examine the arguments made by
Canadian feminists about the need for change in the ways that health
research is stmctured and carried out in this countiy, particularly with
respect to the generation of knowledge about women's health.
Part one of this analysis examines the nature and extent of the
problem of gender-biased research. Itis followed by an overview of the
regulatory framework within which health research is cun-ently conducted in Canada. The third part of this discussion provides a feminist
analysis of the major arguments raised by those who seek to maintain
the exclusionary status quo. Part four reflects upon the impact of political action for change taken by women's health activists. Recognizing
that Canadian feminists have, to date, been more successful in influencing change through public activism in the political arena than through
efforts to work within the dominant research institutions, the paper concludes with a brief assessment of the prospects for legislative intervention.

I. INTRODUCTION

Striking parallels exist between the histories of the Western institutions of law and medicine in te1ms of dominant underlying values and
styles of discourse. Linear rationality and repeatability of results are key
doctrines in the methodologies of both. Other shared features include an
t Erin Skim1er graduated from the combined LLB/MHSA program at Dalhousie University
in May 2001.
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unquestioned commitment to positivism, a belief in objectivity and the
ability to locate absolute truth through reasoned inquiry, the centrality of
the rational individual, and views of civilized society as opposite to a
violent state of nature. Similarly, one particular set of interests has been
overwhelmingly represented throughout the rise of both institutions: the
privileged social class of wealthy and highly educated white men.
Many feminists contend that liberalism, which forms much of the
ideological basis upon which both law and medicine are founded, has
played a critical role in the construction of patriarchy in Western societies.
Feminists have pointed to writings by influential liberal thinkers which
espouse a fundamental belief that the female body is inherently pathological, such that" ... women's bodies, women's minds, and women's natures
are essentially and dangerously inferior to those of men." 1 Women's
unique reproductive capacity was central to this notion.
The concept of women as other - distinct from and less natural than
men - has been a powerful and enduring concept. For example, as
recently as 1979 the Supreme Court of Canada ruled that a federal law
distinguishing pregnant persons from non-pregnant persons did not
constitute unequal treatment of women and men. Bliss v. AttorneyGeneral of Canada2 illustrates the extent to which social inequality and
scientific notions of biological difference are inter-related in traditional,
androcentric legal thinking:
... [T]he Supreme Court used maleness as the standard against which
pregnant women were compared. The absence of an analogous physical condition or equivalent life experience to pregnancy for men meant
that there were not two similarly situated groups that could be compared to determine whether there was equal or unequal treatment. In
doing so, they used the male body as the inaiiiculate major premise
and differential treatment and special burdens could be imposed on
women without there being any formalistic 'inequality. ' 3
1

K. Pauly Morgan, "Contested Bodies, Contested Knowledges: Women, Health, and the
Politics of Medicalization" in The Politics of Women's Health; Exploring Agency and Autonomy (Philadelphia: Temple University Press, 1998) 83 at 102 [hereinafter Exploring
Agency and Autonomy].
2
[1979] 1 S.C.R. 183. This approach to equality was overturned by the Supreme Court of
Canada in Laiv Society of British Columbia et al. v. Andrews et al., [1989] 1 S.C.R. 143
[hereinafter Law Society].
3
S. Martin, "The Control of Women through Gender-Biased Laws on Human Reproduction" in R. Devlin, ed., Canadian Perspectives on Legal Theo1y (Toronto: Emond-Montgomery, 1991) 291 at 297.
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This formalistic approach to equality rights is central to the classic
liberal vision of a fair society in which, as the Bliss case suggests, male
experience is held to be the norm.
Fortunately, Canadian courts have now rejected formal equality as
incompatible with social values in the Charter era and a more substantive concept of equality has emerged.4 Nonetheless, the idea that all
individuals should be treated similarly, regardless of differing social
realities, remains an appealing, deeply-rooted principle in this society
where a liberal-democratic ethos is the dominant paradigm. Subsequently, and to a certain degree inescapably, liberalism tempers gender
relations in all Canadian social contexts. The health care arena is no
exception.
The general theory advanced by many feminists is that sexist presumptions are an inherent feature of traditional medical scientific discourse and continue to exe1i significant influence upon decision-making
in health research. Many of the questions and problems historically
identified as medically important (with the critical exception of female
reproductive capacity), as well as the investigational approaches used to
study those questions and problems, have tended to focus exclusively on
the male half of the human species. A large knowledge gap exists as a
result of this approach: comparatively less is known about women's
health, beyond the limited scope of reproduction, than is known about
men's experiences with health and disease. Consequently, women are
frequently exposed to inappropriate, ineffective, and potentially dangerous medical interventions and information.
My own analysis of the situation is that the feminist position on this
apparent inequity has gained a large measure of public credence, which
has been reflected in a variety of political successes. The prospect for
meaningful systemic change towards more equitable research practices
is heavily constrained, however, by structural features of the medicolegal framework within which research is regulated in Canada. More
paiiicularly, the lack of a cohesive regulatory regime means that accountability for how public research monies are invested is highly
diffuse; individual researchers, funding councils, and the phannaceutical industry essentially hold the reins in detennining the extent to which

4

Law Society, supra note 2.
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women's health concerns are reflected in the research agenda. At
present, research regulation is a murky zone of law, medicine, and
politics and the diffusion of accountability makes it exceedingly difficult to dispel widespread, deeply-rooted "scientific" myths about the
concept of women's health and its social value in contributing to social
equality. I propose that this state of affairs is highly incompatible with
Canada's commitments to advancing women's equality and that legislative intervention is essential to overcoming the structural barriers to
change.

II. NATURE AND EXTENT OF THE PROBLEM OF
EXCLUSIONARY RESEARCH PRACTICES
'Women aren 't just asking/or pink walls, a warm speculum and kinder
doctors.' In fact, we're not asking, at all. We are engaged in a political
fight for shared knowledge, for collective power, for health, for bodily
integrity - for ourselves, our communities, and our world. 5

Calling attention to male-biased research norms is part of the
broader women's health movement through which feminists seek to
challenge the legitimacy and paternalism of institutionalized medical
science. The dominant medical paradigm understands health to be simply the absence of disease. Feminists like Margaret Lock6 and Ruth
Macklin7 are critical of this model and its view of human bodies as
nan-ow entities whose health status is determined by nature-given physiological and genetic features. Rooted in l 91h century reductionist theories of biology, the disease-based construct ignores the potential impact
of social dynamics upon an individual's experiences with illness and
health. Consequently, reproductive capacity is seen to be the only substantive difference leading to varying health experiences between men
and women. This focus on disease fosters a competitive, highly
Pauly Morgan, supra note 1 at 115 (citing P. Williams, "Sick of Dying: Neglect,
Misinfonnation, and Gender Bias have Festered Unchecked in Women's Health Care"
Homemaker's Maga:::ine (November/December 1996) 46 at 49.)
6 "Situating Women in the Politics of Health" in Exploring Agency and Autonomy, supra
note 1, 48.
7
"Women's Health: an Ethical Perspective" (1993) 21:1 J. Law, Med. & Ethics. 23.
5
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technologized race to locate, within the body, ultimate sources of disease causation in order to develop successful treatment interventions.
There are enonnous financial stakes in the race to provide cures and halt
disease progression. Thus, any attempt to uproot the disease model or
cross-pollinate it with alternative models will face considerable resistance.
Feminists are not alone in pointing to the eITors inherent in the
biomedical disease-based model of health. In 1981 the World Health
Organization (WHO) enunciated a broader alternative concept known as
the determinants model. Health was accordingly redefined as "a complete state of physical, mental and social well-being, not simply the
absence of disease or infinnity."8 Recognition of a political dimension
to the relative health of individuals and social groups is a key aspect of
the feminist divergence from the disease model of health.
The gendered lines of oppression in societies are reflected in patterns
of how women are treated by the health care system both as patients and
as active participants, and the detenninants approach is expanded to
include gender as a detemtinant of health. In much the same way, the
marginalization that occurs through racism in Canadian society is an
important health detern1inant. From the detenninants perspective, the
experience of multiple discrimination in society will often be reflected
in reduced health status among women of colour. In a significant departure from the traditional reproduction-centred view, feminism
reconceptualizes women's health as involving " ... women's emotional,
social, cultural, spiritual and physical well-being, and it is determined by
the social, political and economic context of women's lives as well as by
biology."9 Women-specific health information, generated through research, is seen as critical to improving both the well-being and relative
social equality of women. In addition to reconstructing the definition of
health and calling for more info1mation to reflect women's health interests, feminists contend that traditional research methods themselves are
:fundamentally biased.
8

Ibid. at 24.
National Forum on Health, "An Overview of Women's Health" in Canada Health
Action: Building on the Legacy Vol. II (Ottawa: National Forum on Health) 3 (citing S.
Phillips, "The Social Context of Women's Health: Goals and Objectives for Medical Education" (February 1995) 154:4 Canadian Medical Association J. at 507) [hereinafter National
Forum on Health].
9
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1. Manifestation of Gender Bias in Research
According to feminist sociologist Margrit Eichler, bias against
women as subjects in the research process manifests in four main ways:
androcentrism; overgeneralization; gender insensitivity; and the use of
double standards. 10 A review of international articles published in 1989
by the New England Journal of Medicine found, using Eichler's framework, that 80% of original research articles published in that year
contained at least one fonn of gender bias. 11
Androcentricity involves a presumptive reliance on the male paradigm or male-centered world view, which most often means that women
are consciously excluded from subject populations. This has the effect
(intended or otherwise) of pre-emptively eliminating any potential findings of difference in results between men and women. In so doing,
women's different biological and social realities that impact on health
status are rendered invisible.
Overgeneralization of findings often follows from androcentric research designs. In such instances, study results are presented in a tmiversally applicable manner, while in fact it is unknown whether such is true
because the study was conducted entirely on one gender (usually male).
The double standard bias involves " ... evaluation, treatment, or measurement of identical behaviours, traits, and situations by different
means." 12 One of the best known examples of this biased approach was
seen in early findings from the Framingham Heart Study (a long-tenn
continuous study started in 1948). 13 Initially, researchers simply dismissed complaints of chest pain among female subjects as essentially
harmless, in contrast to similar complaints by male subjects, which were
deemed highly significant. The different treatment stemmed from the
presumption that the male subjects were more likely than the female
subjects to experience heart attacks and sudden death as a result of their
L. Wallis, "Why a Cufficulum on Women's Health?" in A. Dan, ed., Reframing
Women's Health: Multidisciplinary Research and Practice (Thousand Oaks, Calif.: Sage,
1994) [hereinafter Reframing Women's Health]; also cited by Y. Lefebvre, Women's Health
Research in Canada (Ottawa: Health Canada, 1996) (paper prepared for the Canada-USA
Fornm on Women's Health).
11 K. Williams & E. Borins, "Gender Bias in a Peer-Reviewed Medical Journal" (1993) 48
J. American Med. Women's Assoc. 160 (cited by Lefebvre, ibid. at 6).
12 Refi'aming Women's Health, supra note 11 at 19
13 B. Healy, A New Prescription for Health; Getting the Best Medical Care in a Man's
World (New York: Penguin, 1995) at 332-333.
10
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chest pain. This was consistent with prevailing op1111ons that heart
disease was a man's disease and that women were hypochondriacs.
Subsequent research concluded, however, that women's chest pains are
indeed indicative of very real, potentially dangerous heart conditions
that are not typically seen in men. By applying a double standard to the
early reports from research subjects, the Framingham researchers had
essentially validated the existing myths by applying a "scientific proof'
label.

2. Pervasiveness of Bias in Canada
As the New England Journal of Medicine study indicates, the extent
to which gender bias pervades medical research is significant. While no
parallel study has analyzed the contents of Canadian medical journals,
gender biased research appears to be the nonn in this country. In 1994,
the Advisory Committee on Women's Health to the Medical Research
Council of Canada (MRC, the largest source of federal research funding) attempted to assess the extent to which it historically funded
women's health research. Problems associated with data availability,
definition of research designs, interpretation of findings, and unrecorded
research activities made it clear that the MRC lacked the capacity to
accurately review the gender dynamics of the research it had itself
funded. 14 Interestingly, the MRC study detennined that roughly 5% of
its funding was invested into women's health issues while a similar
study of research funding led to the estimate that 7% of funding was
directed towards men's health issues. As Lefebvre notes, "[t]hese figures of course imply that the remainder of the research funded is general
neutral, which is probably inaccurate."15 Such findings suggest that
gender insensitivity and other forms of bias exist in 88% ofMRC funded
research.
An impo1iant overall trend, moreover, is the fact that the vast majority of funded research with an explicitly gendered approach focuses
exclusively on reproductive matters. This reflects the pre-eminence of a
reproduction-centered view of women's health. Analysis of research
funded in 1994-95 by the National Health Research Development Program (NHRDP) revealed that 70% of its total investment in women's
14

15

Lefebvre, supra note 11 at 4-5.
Lefebvre, supra note 11 at 6.
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health issues went to reproductive studies, a broad category which
included investigations into the health of newborn infants (a group
which hardly fits into the category of 'women' at all).
3. Implications for Women
Generally, the impact of systemic marginalization of women in
health research results in skewed treatment of some health problems and
non-treatment of other concerns peculiar to women that have not been
taken seriously by the health care establishment.
Specific examples abound. In 1977-78, for instance, Canadian feminists Leah Cohen (a social scientist) and Constance Backhouse (a lawyer) identified the following disturbing patterns: 16
•

•

•

•

overmedication of women, particularly with mood-altering
drngs,
high rates of unnecessary surgeries on the women, in particular
hysterectomies, breast surgery, and cesarean section births,
estrogen replacement therapy targeted to women pathologized
simply by virtue of going through menopause,
the frequency of crisis-oriented, technology-managed hospital
births along with the absence of 'legitimate' alternatives such
as home births,
suppressed information about the legality of abortion, hospitalintroduced delays and quotas, and restricted access to abo1iion
services, and
negligence, avoidance, and trivialization of female rape victims
by many physicians and health care professionals in emergency
rooms.

In 1998, Morgan contended that all of these patterns remain relevant
concerns for Canadian women. 17
Particular attention has been directed towards the situation of
women as consumers of pharmaceutical products that have been tested
only on male subjects in clinical trials. Despite the reasons suggesting
16

"Women and Health: the Growing Controversy" 1:4 Can. Women's Studies 4-10 (cited
by Morgan in Exploring Agency and Autonomy, supra note 1 at 83.)
17
Exploring Agency and Autonomy, supra note 1.
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that the conventional approach of testing drugs on men and generalizing
the results to women may not be effective or appropriate, this has long
been a widespread norm in Canada, 18 as elsewhere. As will be discussed
below, some recent change has been seen at the federal level through
introduction of the Guidelines on Inclusion of Women in Clinical Trials19 under the auspices of the Food and Drugs Act. 20

Ill. REGULATION OF HUMAN EXPERIMENTATION IN CANADA
In Canada, research involving human subjects is a quasi self-regulating industry that operates within a broad legal framework but under few
specifically directed legislative provisions. Legal problems that arise in
relation to questionable research practices can be addressed through a
wide variety of mechanisms including courts of law (in cases where
criminal charges are laid or civil actions for damages are pursued),
public administrative bodies (research funding organizations, for instance), or professional associations' internal disciplinary proceedings. 21 In practice, administrative bodies make most decisions stemming from potential legal quandaries and courts of law are used only in
rare circumstances. The true locus of accountability for research involving human subjects in Canada is the individual research ethics boards
(REBs) which are located in virtually every institution where research
takes place. These committees do not look to laws but rather to codes of
ethics, guidelines, and policy statements for guidance when dealing with
quandaries in human research.
1. Federal Statutory Provisions
In an extremely general sense, the provisions of the Criminal Code 22
can be presumed to apply to researchers in the same general sense that

18

National Fomm on Health, supra note 10 at 4.
Inclusion of Women in Clinical Trials, Therapeutic Products Programme Guidelines
(Ottawa: Health Canada, April 1997).
20
R.S.C. 1985, c. F-27.
21
Law Refonn Commission of Canada, Biomedical Experimentation Involving Human
Subjects (Working Paper 61) (Ottawa: LRCC, 1989) at 7.
22
R.S.C. 1985, c. C-46.
19
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the criminal law applies to all Canadians. 23 Verdun-Jones and Weisstub
contend that researchers generally overlook the potential impact of
criininal law in the research context and focus instead on avoiding civil
litigation. 24 No record has been found of criminal charges being laid
under Canadian law against any researcher engaging in human experimentation. The criminal law plays a minute and peripheral role in
ensuring acceptable standards of research involving humans.
The Law Reform Commission of Canada (LRCC) has recommended a series of general amendments to the Criminal Code to make it
more relevant to research activities. Among the numerous reasons cited
as evidence of a need to amend the criminal law, the LRCC contends
that there should " ... be consistency of thought and action ... " among
provinces with respect to research standards of conduct.25 As this reasoning indicates, the lack of a national legal framework and corresponding diffusion of authority for decision-making in human research has led
to substantial variance in ethical norms across the country.
The federal Food and Drugs Act26 and accompanying regulations
govem the introduction of new phannaceutical products to the Canadian
consumer market. The legislative scheme specifies the conditions that
manufacturers must meet prior to distributing new pharmaceutical products to researchers for clinical testing, which is a prerequisite to obtaining government consideration for approval of a new drug. 27 "These
conditions provide a basic level of protection for experimental subjects
who agree to have new chemical substances tested on them. The regulations also stipulate that researchers must strictly monitor the use of
medications, indicate any serious incidents resulting from their administration, and submit a detailed report."28
While generally applicable, the Criminal Code makes no express or implicit reference to
medical research in any of provisions. Among other recommendations, the LRCC has said that
"The Criminal Code should be amended by the addition of a provision which excludes from
offences against bodily integrity those cases of non-therapeutic biomedical experimentation in
which free and infonned consent is properly obtained and the risks incmred are not disproportionate to expected benefits.": LRCC, supra note 22 at 35.
24
"The Regulation of Biomedical Research Experimentation in Canada: Developing an
Effective Apparatus for the Implementation of Ethical Principles in a Scientific Milieu"
(1996-97) 28:2 Ottawa L.R. 297 at 305.
25
LRCC, supra, note 22 at 59.
26 Supra note 21.
27 LRCC, supra note 22 at 12.
28 LRCC, supra note 22.
23
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Canada's only formal regulatory statement mandating the inclusion
of women in any research context operates under the authority of the
Food and Drugs Act and Regulations. 29 In April of 1997 Health
Canada's Therapeutic Products Programme (TPP - also known as the
Drugs Directorate), which administers and evaluates new drug submissions from industry, established Guidelines on Inclusion of Women in
Clinical Trials. The Guidelines establish that sponsors of clinical drug
trials must enroll both men and women " ... in the same trials in numbers
adequate to allow detection of clinically significant sex-related differences in drug response."30 Where significant differences are found to
exist, researchers will be required to develop gender-specific prescribing infonnation and warnings before the drug can be approved for
marketing. While there are no formal penalties for failure to adhere to
the Guidelines, certain administrative incentives within the TPP encourage compliance among drug trial sponsors: "It's in their best interest as
the review can take much longer if we ask them for infonnation they
don't have on file or better yet, in their submission."31
The creation and implementation of these Guidelines within the
Food and Drugs Act regulatory scheme is a significant development and
is largely attributable to the advocacy work of women's health activists. 32 It is important to appreciate, however, that it operates exclusively
in relation to government approval of new pharmaceutical products which is only one feature of the much larger research landscape.

2. Provincial Provisions
Interestingly, despite an apparently high level of anxiety within the
research c01mnunity about the potential for private action, 33 Canadian
casebooks have reported very few civil actions for damages incurred in
29

LRCC, supra note 22.
Supra, note 20 at 2. Note, however, the subsequent proviso: "In some cases, however, it
may be appropriate to conduct studies in a single sex (e.g., to evaluate the effects of phases of
the menstrual cycle on drug response).
31
A. Goldstein, Health Canada (Therapeutic Products Programme) personal communication, October 26, 1999 (on file with author).
32
F. Baylis, J. Downie & S. Shetwin, "Reframing Research Involving Humans" in
Exploring Agency and Autonomy, supra note l at 238.
33 Verdun-Jones & Weisstub, supra note 25; V. Me1ion, "The Exclusion of Pregnant,
Pregnable, and Once-Pregnable People (a.k.a. Women) from Biomedical Research" (1993)
XIX:4 Am. J. Law & Med. 369 at 400.
30
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the course of research. Of the small number that are reported, only two
arose in the direct context of fonnal research projects; 34 several other
cases relate to damages arising where practitioners have administered
innovative or novel treatments that the professional mainstream viewed
as untested and unsound. 35 In all instances, the primary issues related to
the information provided by the researcher prior to the participant's
decision to consent.
From the caselaw, it is clear that the relevant standard of disclosure
increases sharply when a medical intervention is deemed to have a
strongly experimental component. In cases where the intervention has
no intended potential direct to the participant (i.e. the intervention is
"non-therapeutic"), the participant's consent will not be held as valid
unless it was granted after all risks, no matter how remote, were disclosed. 36 This is, however, virtually all the information provided by
Canadian caselaw regarding the legal duties owed by medical researchers in respect to prospective research subjects.
The province of Quebec is the only jurisdiction in Canada to have
enacted specific legislative provisions regulating activities relating to
human experimentation. In response to quandaries arising in conjunction with early heart transplantation procedures, sections 18 to 25 were
added to the chapter on "Enjoyment of Civil Rights" in the Civil Code
(CCQ). Like the common law elsewhere in Canada, these provisions
held that the major legal requirements for research on humans were that
the subjects provide free and infonned consent and that the risks ofhann
must not outweigh the anticipated benefits of participation. 37 Unlike the
common law, however, the CCQ goes further and establishes specific
requirements for research involving children and adults who lack capacity to consent. 38 These provisions further provide a statutory basis of
authority for institutional research ethics boards to judge the ethical
soundness of research activities in the province of Quebec.
34
Halushka v. University of Saskatchewan et al. (1965), 53 D.L.R. (2d) 436 (Sask. C.A.)
[hereinafter Halushka]; Weiss v. Solomon (1989), 48 C.C.L.T. 280 (Que. S.C.) [hereinafter
Weiss].
·
35 OJ1derma11 v. Ringrose (1978), 89 D.L.R. (3d) 32 (Alta S.C.); Zimmer v. Ringrose
(1981), 28 A.R. 69 (C.A.); Coughlin v. Kunt:: (1987), 17 B.C.L.R. (2d) 365 (S.C.)
36 Halushka, supra note 35; Weiss, supra note 34.
37 LRCC, supra note 22 at 13.
38 Art. 21 C.C.Q.
39 Verdun-Jones & Weisstub, supra, note 25 at 317.
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3. Research Ethics Boards and the Ethics Review Process
Outside of Quebec, REBs do not operate under any enabling legislation but rather under the by-laws and policies of the hospitals, universities and other organizations in which REBs are housed. REBs " ... have
no independent power to require that research protocols involving human subjects be submitted to them for prior approval."39 Public funding
agency rules provide the most compelling practical source of authority
for the REB role in research review in Canada. The Canadian Institutes
for Health Research (CIHR, formerly the Medical Research Council of
Canada), the Social Sciences and Humanities Research Council
(SSHRC), and the Natural Sciences and Engineering Research Council
of Canada (NSERC) are the country's largest sources of public funding
for research in those respective fields. They stipulate that they will only
fund research initiatives that are approved by an REB in an institution
that has certified compliance with the Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans. 40
The general procedure for ethical review is similar in public institution-based REBs throughout Canada. 41 Before a researcher commences
research activities on human subjects, he or she first submits a research
protocol describing the project's proposed purpose, methodology, and
safety precautions to the REB of the institution or facility where the
research will take place. After an ethical and scientific review is completed, the REB typically approves the protocol, approves it with specified modifications, or disallows it altogether.42 A 1995 study found that
among the one hundred REBs associated with medical schools in
Canada, all approve most protocols submitted for review and request
only minor modifications. 43 While the terms of reference of many REBs
indicate a responsibility for on-going monitoring, the reality is that due
to intense resource constraints, the monitoring function has traditionally

40
Medical Research Council of Canada, Natural Sciences and Engineering Research
Council of Canada, Social Sciences and Humanities Research Council of Canada, (Ottawa:
Agency, 1998) at i-1 [hereinafter Tri-Council Policy Statement].
41
F. Baylis et al. eds., Health Care Ethics in Canada (Toronto: Harcomi Brace, 1995) at 322.
42
Ibid.
43 The NCBHR study found that 22% of submitted protocols were approved as first
presented, 75% were approved with minor modifications, and 3% were rejected outright (in
Verdun-Jones & Weisstub, supra note 25 at 322).
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been often minimal or non-existent. 44 This pattern should change, however, as the Tri-Council Policy Statement now expressly requires continuing review processes for research projects that are over one-year in
duration and those that are seen to pose significant risks. 45
Numerous critics have questioned the ability of this model of monitoring to ensure that socially acceptable standards of conduct are upheld
in research involving human subjects. A 1995 report by the National
Council on Bioethics in Human Research (NCBHR) found that Canadian REBs exercised review powers over almost all of the research
initiatives being undertaken within their host institutions. The NCBHR
repo1t further found that the existing review model is under-inclusive,
however, in that it provides no assurance that research outside the scope
of an REB's institutional authority will be reviewed for consistency with
acceptable standards of conduct.46 There is no formal requirement that
privately-funded research conducted outside of hospitals and universities be subject to ethics review or, moreover, be required to conform
with accepted ethical nonns.
Further questions about the effectiveness of this model relate to the
sanctions that can be imposed for non-compliance with REB recommendations. Given the lack of statut01y authority, the primary sanctions
available are withholding of grant monies and denial of opportunity to
publish in some international medical journals. 47 The Law Reform
Commission has spoken on this point as well, positing that in addition to
amending the Criminal Code, 48 the Parliament of Canada should enact
general legislation on human research that prescribes state-sanctioned
penalties for non-compliance. 49 Furthermore, the Tri-Council Policy
Statement requires institutions to vest their REBs with authority to
withdraw initial approval and effectively halt research projects when it
is detennined that unethical practices are occmTing. 50
Verdun-Jones & Weisstub, supra note 25 at 325.
Tri-Council Policy Statement, supra note 41 at 1.10.
46
Verdun-Jones & Weisstub, supra note 25 at 320.
47
M. Fox, "Research Bodies: Feminist Perspectives on Clinical Research" in S. Sheldon &
M. Thomson, eds., Feminist Perspectives on Health Care Law (London: Cavendish, 1998)
115 at 120-121 [hereinafter: Feminist Perspectives on Health Care Law]; Verdun-Jones &
Weisstub, supra note 25 at 327.
48
Supra note 23.
49
LRCC, supra note 22 at 59.
50
Tri-Council Policy Statemellt, supra note 41 at A1i. 1.2.
44
45
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Another set of concerns surround the dual function most REBs serve
in reviewing and assessing the soundness of both the scientific and
ethical dimensions of proposed research projects. The main problem is
that REBs have generally been "dominated by scientists and researchers, even though the fundamental ethical issues facing the REBs cannot
be resolved by applying an exclusively scientific or technological expertise. "51 The Tri-Council Policy Statement now mandates that REBs
must have a broad membership, including both men and women. The
minimum requirement is that each REB must have two members with
research expertise, one who is "knowledgeable in ethics", one who is
"knowledgeable in the relevant law", and one who is not affiliated with
the REB' s institution but represents the community that is served by the
institution. 52 While this is an important development in theory, it is hard
to ascertain its practical implications. In the past, where lay members
have been encouraged to participate in ethics review, they have tended
to be disempowered. Lacking research expertise, they have often been
" ... dependent of researchers for information regarding research practices. "53
4. Codes of Ethical Conduct in Human Research
When ethical questions emerge in the course of a protocol evaluation, REB members consult codified statements of ethically acceptable
conduct. While some universities and research institutes have developed
their own internal Codes or Guidelines, the most influential statements
in Canada have emanated from the Medical Research Council (now
CIHR). Unfortunately, with respect to the issues surrounding inclusion
of women in research, the Tri-Council Policy Statement does more to
create uncertainty than provide guidance.
Research ethics codes reflect formal repudiation of medical
science's tradition of exploiting oppressed peoples for research purposes. For example, enslaved black women and poor white women were
subjected to experimental gynaecological surgery in the United States in
the nineteenth century, with one woman known to have survived thirty
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Verdun-Jones & Weisstub, supra note 25 at 323.
Tri-Council Policy Statement, supra note 41 at 1.3.
Fox, supra, note 48 at 121
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separate invasive procedures. 54 While it was long customary for researchers to use people in disadvantaged social classes for experimental
purposes, international moral opprobrium was voiced for the first time
during the post-war Nuremberg trials.
Codifying the major principles of consensus has not, however, put
an end to exploitative research practices. Subsequent transgressions
gaining international notoriety since the Nuremberg Trials have included: the Tuskegee Study where standard antibiotic treatment for
syphilis was withheld, for a forty year period, from four hundred infected black men and 55 the Jewish Chronic Disease Hospital in Brooklyn where patients suffering from chronic debilitating conditions were
involuntarily injected with live cancer cells as part of a cell rejectionrate study. 56 The dominant approach to research ethics, which is reflected in the Tri-Council Policy Statement and the earlier MRC Guidelines, primarily aims to curb abuses like these where people are deliberately misled or involuntarily recruited to serve as research subjects. To
this end, mainstream research ethics emphasizes the fundamental value
of individual rights to autonomy, dignity, and bodily integrity.
Feminist bioethicists concur that all individuals must be free to
refuse to participate as research subjects and that the potential hanns
should not outweigh the potential benefits of agreeing to participate.
However, feminists diverge from traditional bioethics literature, when
they draw attention to the gender dynamics inherent in both the underlying theory and the patterns that emerge through practical adherence to
the mainstream principles. The principle of autonomy, for instance, is
generally thought of in a highly individualistic manner, focussing
mainly on the potential research subject's relative freedom to refuse to
participate as a research subject. This approach effectively removes
from consideration the social context which influences how potential
participants exercise their power to choose. "Rather than just asking
whether research subjects truly understand all relevant details about
their involvement (a question we still consider important), we argue that
questions must also be asked about who is invited to participate and who
S. Harding, Whose Science? Whose Knoivledge? (Ithaca, N.Y.: Cornell University,
1991) at 204.
55 S. Sherwin, No Longer Patient: Feminist Ethics and Health Care (Philadelphia: Temple
University, 1992) at 162-163 [hereinafter No Longer Patient].
56 Ibid.
54
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is not and how the specific research questions were selected."57 True to
the form of its predecessors, the Tri-Council Policy Statement ignores
these kinds of questions and retains the traditional emphasis on individual liberty rights.
The Tri-Council Policy Statement indicates in commentary passages
that "[w]hether intentional or inadvertent, the exclusion of some from
,the benefits of research violates the commitment to societal justice."58 It
continues to state that "distributive justice imposes on researchers and
REBs a duty not to act in a discriminating fashion." 59 Unfortunately,
neither of these important principles is reflected in the fonnal Articles
that follow.
Under the heading "Research Involving Women", the Tri-Council
Policy Statement provides one simple Aliicle: "Women shall not automatically be excluded from research solely on the basis of sex or
reproductive capacity."60 The accompanying narrative states some imp01iant principles but gives little in the way of concrete direction to REB
members who may be struggling with the exclusion criteria in a particular research protocol.
Clearly, the Tri-Council Policy Statement is ill-equipped to assist
REB members who make the ultimate decisions on issues relating to the
inclusion of women in research. Given that this statement is the major
source of rules for researchers operating with grants from CIHR,
SSHRC, and NSERC, Canada's largest public research funding agencies, its inadequacy is staggering. One cannot avoid concluding that the
Tri-Council Policy Statement is complicit with the medical
establishment's traditional bias towards men's interests over women's
interests in health and broader social equality.

57
S. She1win, "A Relational Approach to Autonomy in Health Care" in Exploring Agency
and Autonomy, supra note I at 39-40.
58
Tri-Council Policy Statement, supra note 41 at 5.2.
59
Tri-Council Policy Statement, supra note 41.
60
Tri-Council Policy Statement, supra note 41 at 5.3.
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IV. FEMINIST ANALYSIS OF JUSTIFICATIONS FOR
THE EXCLUSIONARY NORM

Proponents of the traditional status quo in research generally raise
four justifications when forced to defend practices that marginalize
women. These are the need for scientific rigour and gender uniform data,
prohibitive monetary expense, fetal protection and avoidance of potential liability. However these arguments favouring maintenance of the
exclusionary status quo reveal the persistence of deeply and dangerously
traditional views of women. None of these justifications for exclusionary research practices is tenable from a feminist perspective. These
excuses do not reflect an interest in the promotion of women's health but
rather in protecting the particular interests of the medical research
establishment.
1. Locating the Roots of the Exclusionary Phenomenon

One explanation for the persistence of the liability-avoidance excuse
is gender-biased misunderstanding of the informed consent doctrine
within the research community. Justice Ellen Picard has observed that in
the 1980s and 1990s, examples could still be found in Canada where
doctors and hospitals refused to accept the consent of a woman to
medical treatment, clinging to the belief that women and girls could not
provide valid consent and that husbands and fathers were the more
legitimate decision-makers. 61 The underlying issue is general equivocation around women's autonomy rights and capacity to make reasoned
healthcare decisions. This has been particularly evident in abortion
debates.
In the 1989 case Tremblay v. Daigle, 62 the Supreme Court of Canada
overturned a lower court's injunction which prohibited a woman from
obtaining an abortion on the grounds that her former common law
partner objected. The Quebec Court of Appeal trivialized Ms. Daigle's
reasons for seeking to te1minate the pregnancy and devalued the harms
she believed would result to her if the pregnancy were can-ied to term. 63
61 E. Picard & G. Robertson, Legal Liability of Doctors and Hospitals in Canada, 3d ed.
(Scarborough, Ont.: Carswell, 1996) 60.
2
6 [ 1989] 2 S.C.R. 530.
63 Martin, supra note 3 at 305.
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On appeal, the Supreme Court rejected this reasoning and held that a
potential father does not hold a legal right to veto a woman's decision to
tenninate pregnancy. As this judgement clearly indicates, there is no
legal requirement for medical professionals to seek consent from a
woman's spouse or any other person prior to commencing any medical
intervention. Uncertainty about the validity of autonomous consent by
women to participate as medical research subjects may nonetheless
continue to linger, particularly where researchers have a strongly paternalistic orientation towards potential fetuses.
The distmst shown by both legal and medical institutions in Canada
in the ability of women to make autonomous decisions about their
reproductive capacity, and their health more broadly, suggests outdated
views of women as essentially non-rational beings who should be divested of power to control their bodies.
Exclusionary research practices may also reflect the idea that researchers and research funders attach priority to the health issues that
they personally fear. 64 Given that researchers and those who make
funding decisions have historically been men, the lack of attention
directed to women's health (with the exception of women's reproductive capacities) makes sense. This is reinforced by the system of research
funding. "Researchers do not pursue whatever projects come into their
heads but those for which they can receive funding. Needing to attract
grant money and produce results, they shape their research interests to
serve the orientations of funding sources."65 From this perspective,
where key decision-makers are predominantly white, upper to middle
class men, the research agenda can be expected to reflect the interests of
that social group. 66
It is worth noting that while the number of women in the medical
profession has grown considerably in Canada, women continue to hold
fewer leadership positions than men do. Institutional priorities can
subsequently still be seen as stmctured around gendered concepts despite the influx of women.
6-1 Melion, supra note 34 at 373 cites US Congressional Representative Patricia Schroeder
as saying, "[Y]ou fund what you fear. When you have a male-dominated group of researchers,
they are more won-ied about prostate cancer than breast cancer."
65
Sherwin, No Longer Patient, supra, note 56 at 17.
66
Fox, supra, note 48 at 126; S. Rosser, "Gender Bias in Clinical Research: the Difference
it Makes" in Refiwning Women's Health, supra note 11.
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Probably of more fundamental importance than the sheer number of
women in medicine and research, however, is the dominance of scientific research methods that pose as gender-neutral while contributing to
highly gendered health implications. One group of feminists writes:
Science is not a value-neuh·al activity in practice, nor should it aspire
to be. The demands of disinterestedness do promote, not better science, but rather science that preferentially serves some interests and
neglects others by blocking efforts to expose that fact by denying and
thereby hiding the interests that are operative. When the determinate
interests are those of the dominant group(s) in society, they seem to be
both natural and general since they blend seamlessly with the cultural
dominance of those groups in all spheres of activity. It is only when the
particular interests of marginalized groups (i.e., those who are subject
to oppression) that appear to be 'special interests' that threaten to
contaminate otherwise 'pure' scientific methods. 67

This line of argument is a strong departure from the long-held view
of scientific researchers as objective, value-neutral investigators. 68
Feminist standpoint theorists contend that knowledge, which represents
the sum of a society's opinions and best beliefs, is unequivocally a
socially-grounded phenomenon. Accordingly, knowledge-generators
are seen as heavily influenced by the dominant social constructs of the
milieu in which they function. 69 While this view of the role of the
researcher is generally accepted in the social science disciplines, it is
met with significant resistance from quaiiers of the research community
that associate themselves with the so-called 'hard' or 'pure' positivistic
fields. Thus, researchers identifying with the classic biomedical disease
model of health are usually highly skeptical of feminist epistemological
theory and extremely critical of the notion of a researcher as an active
participant who influences the results of the research process.
In a revealing parallel, similar lines of debate are often heard within
Caiiada' s legal community regarding the adjudicative function. Since
the 1970s, feminists have been instrumental in challenging the long-held
view of the judge as a truly neutral arbiter. 70 While the standpoint
approach to knowledge-as-truth and the use of knowledge in decisionBaylis, Downie & Sherwin, supra note 33 at 237.
Supra note 33 at 236.
69 Harding, supra note 55 at 302-303.
70 N. Wikler, "Identifying and Correcting Judicial Gender Bias" in S. Martin & K.
Mahoney, eds., Equality and Judicial Neutrality (Calgary: Carswell, 1987) at 254.
67

68
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making has gained a certain level of credence on a theoretical level,
there is marked discord over the practical implications of taking this
jurisprudential approach.
The Supreme Court of Canada's four-way split decision in the 1997
case R. v. R.D.S. 71 reflects the enormous degree of controversy surrounding the issue of socially contextualized decision-making on the
bench. Accepting that judges must often incorporate untested presumptions about human and societal nature when making decisions, the
contested issue today seems to be the extent to which (if any) these
presumptions should be recognized and enunciated in a judge's fonnal
reasons. Proponents of the traditional approach suggest that sphinx-like
posturing is necessary and appropriate in many circumstances in order
to avoid needless controversy which may bring the administration of
justice into disrepute. 72 This suggestion completely side-steps the argument that it is the status quo approach itself which has brought the
administration of justice into disrepute and led to views of the system as
catering mainly to the political and economic interests of dominant
social groups. According to critical race theorist Carol Aylward, judicial
silence about social context presumptions permits an unacceptable lack
of accountability. Silence disallows opportunity to guard against reliance on myths and prejudicial beliefs infecting the decision-making
process. 73
While Canadian legal commentators agree that unproven social
context assumptions play a meaningful role in decision-making, there
appears to be no agreement on the question of whether the administration of justice will be improved or compromised if judges are more
explicit in sharing their untested views of social truth in the course of
rendering decisions. In contrast, decision-makers in biomedical research
seem less inclined to accept, even on a theoretical level, standpointbased epistemological arguments about the relationship between social
context and choices exercised in the course of research. While certain
progress has been made in this area, particularly by women in the
research field, 74 mainstream medical researchers and institutions have
[1997] 3 S.C.R. 484.
B. Archibald, "The Lessons of the Sphinx: Avoiding Apprehensions of Bias in a Multiracial, Multi-cultmal Society" 10 C.R. (5t11) 54.
73
"'Take the Long Way Home': R.D.S. and Critical Race Theory" 41 U.N.B.L.J. 61.
74
Harding, supra note 55 at 296-312.
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not yet opened enough to enable feminist reframing of the knowledgegenerating enterprise.
The purpose of this discussion has been to show that general notions
of what constitutes 'good' decision-making in both the judicial realm
and the realm of biomedical research place significant emphasis upon
the role filled by individuals in key positions of authority. Feminists and
other critical theorists have demonstrated that the long-prevailing view
of decision-makers in both realms as purely objective and politically
neutral is itself an inherently ideological position. By exposing this
central fallacy, the notion of 'good' decision-making becomes contestable and the results of supposedly 'good' decisions can be more critically assessed.

v. ACTION FOR CHANGE
The women's health movement and its calls for more inclusive
research practices have made an unmistakable impact upon federal
health policy in Canada. As this section will show, however, it is
uncertain whether the successes won through political channels will
result in meaningful change at the substantive level, where basic decisions about funding and research protocol design are made.
The international women's health movement has grassroots origins,
ste1mning from radical feminists' efforts in the 1970s to encourage
women to reclaim the knowledge and ownership of their bodies. Part of
the broader women's equality movement, the women's health agenda
has moved from its initial fringe position to a central, highly visible one
and has gained wide public support over the past two decades.
Bernadine Healy, a fonner Director of the U.S. National Institutes for
Health, reflects this transition when she states "[i]t is not 'politically
correct,' nor is it radically feminist, to suggest that disease prevention is
critical to the public health of all Americans; it is common sense."75
Nonetheless, the reality that mainstream medicine has not fully embraced the feminist agenda is reflected in the title of Healy' s book: A

75

Supra note 14 at 15.
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New Prescription/or Women's Health; Getting the Best Medical Care
in a Man's World. 76
The starting point for Canadian government recognition of women's
health and research as distinctly important public policy issues was the
1985 Third World Conference on Women in Nairobi. 77 In 1988 the
Department of Health and Status of Women Canada sponsored a national symposium on women's health which led to the creation of a
pennanent Federal/Provincial/Territorial Working Group on Women's
Health to advise the Conference of Deputy Ministers of Health. Publication of the Working Group's first report in 1990 coincided with a period
of intense lobbying of Canadian and American governments by women
with breast cancer. 78 A House of Commons Standing Committee on
Breast Cancer was established in response and increased government
funding for breast cancer research followed shortly thereafter. In 1993
the National Fornm on Breast Cancer research brought together an
unconventional mix of researchers, women with breast cancer, cancer
agency volunteers, physicians, and government policy workers and
demonstrated a high-level commitment to promoting fonns of researching women's health that extend well beyond the biomedical sphere.
Contributing to improved knowledge about women's health was a
component of the Liberal Party's 1992 election platform and the government has followed through with many of its promises in this regard. A
Women's Health Bureau was established at Health Canada in 1993, and
in 1996 Ottawa provided funding to establish five national Centres of
Excellence for Women's Health (CEWH). The CEWH Program has a
six-year lifespan and will provide $2 million ammally to each of the five
Centres during this period. The ultimate objective of the Program" ... is
to improve the health status of Canadian women by enhancing the health
system's understanding of, and responsiveness to, women's health issues. The work conducted by the funded Centres will be policy-oriented
and aimed, ultimately, at making necessary changes to the health system."79 Narrowing the knowledge gap between gender and the other
76

Supra note 14.
Supra note 11 at 2.
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detenninants of health is seen as critical to accomplishing these general
aims.
Health Canada's Women's Health Strategy is the most recent federal
government statement of its commitment to improving women's health
and usage of the health detenninants model in research and policymaking. 80 Among other things, the Women's Health Strategy directly
addresses the need to promote more and better inquires into women's
health across the research spectrum. Health Canada pledges to make the
research programs and activities it supports " ... more relevant to
women's health concerns."81 The CEWH Program is featured prominently in the subsequent statements of intention. Whether or not the
CEWH Program is capable of facilitating change of such magnitude in
the research realm remains to be seen. Prospects do not appear good,
however, given that the Program is designed to be short-lived, and that
the allocated funding is minute relative to the total federal investment in
health research ($10 million annually versus the $500 million the government has pledged to spend from 1999 to 2002). The Women's Health
Strategy further states that additional federal monies will be made
available to support high priority women's health issues. No figures are
provided, however, so the extent of this support is unknown. 82
The Strategy document also makes reference to Health Canada's
relatively new Guidelines on Inclusion of Women in Clinical Trials. 83
The Strategy promises that this policy " ... will be monitored."84 A
medical doctor on staff at Health Canada's Therapeutic Products
Programme (which is responsible for implementing the inclusion
policy) provides the following insight: "To be frank and brutally honest,
while we, the civil servants, are interested in . . . finding out if there are
differences between males and females [in responses to new drugs
studied in clinical trials] ... we all wonder if push came to shove whether
our government would stand up to the companies to require this."85
80

Health Canada (Women's Health Bureau), Women's Health Strategy (Ottawa: Health
Canada, 1999).
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This indication of resistance to the policy by the private sector and
the government's corresponding unwillingness to move from "guidelines" to more coercive measures is revealing. It suggests that, to a
certain degree, the government's oft-avowed commitment to women's
health and an equitable research agenda is mere posturing. The Canadian Women's Health Network (CWHN) is one activist group that has
called on the federal government to intervene more directly to demonstrate that this pessimistic scenario does not reflect reality.
In its February 1999 budget the government announced plans to
significantly increase research funding and to change the organizational
structure of public funding for health research. Aiming to promote a
more collaborative Canadian research sector, the government indicated
its intention to merge health research funding into a single entity called
the Canadian Institutes for Health Research (CIHR). The MRC was
replaced by CIHR and health research funding is no longer distributed
through SSHRC and NSERC. Enabling legislation was passed on November 4, 1999. The new organization was functional by April 1, 2000
and includes an Institute for Gender and Health (one of thirteen Institutes). Promotion of women's health does not appear to be an express
theme within the CIHR structure.
A CWHN working group was active from the outset in pressing
CIHR's government-appointed Interim Governing Council to ensure
that women's health interests would be reflected in the new structure. 86
Among other specific measures, the working group recommended that
the government create legislation mandating the inclusion of women,
children, and minorities in CIHR-funded research activities. 87 The
CWHN working group was seeking legislative intervention modeled on
a U.S. federal statute, the 1993 National Institutes of Health Revitalization Act. 88 This Act directed the National Institutes of Health (NIH), a
federal research funding body with structures similar to the new CIHR,
to establish guidelines for the inclusion of women and mino1ities in
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clinical research. Giving effect to the federal Act, the NIH released
extensive guidelines in 1994 and established the clear policy that NIH
research awards would hinge upon confonnance with the Guidelines. 89
The NIH Guidelines and the companion piece, an 81-page Outreach
Notebook, present a detailed and forceful contrast to the vague statement
from Canada's Tri-Council that "women shall not automatically be
excluded from research solely on the basis of sex or reproductive
capacity."90 Moreover, it is far more broadly applicable than Health
Canada's Guidelines on Inclusion of Women in Clinical Trials. 91
It is unlikely such legislative intervention will transpire in Canada in
the near future given the federal government's 'hands-off' policy approach to the regulation of research involving humans. The Medical
Research Council has consistently advocated against legislation, arguing, among other things that guidelines are more flexible than laws and
thus more adaptable to shifting a social consensus of acceptable
norms. 92 The Tri-Council has taken a similar stance:
.. .legal and ethical approaches may lead to different conclusions. The
law tends to compel obedience to behavioural norms. Ethics aim to
promote high standards of behaviour through awareness of values,
which may develop with practice and which may have to accommodate choice and liability to en. Further, though ethical approaches
cannot preempt the application of law, they may well affect its future
development or deal with situations beyond the scope of the law. 93

Given the inadequacy of the Tri-Council's statement with respect to
inclusion of women in research, and the general criticisms about the
effectiveness of the fragmented model of accountability at present, the
research community does not seem poised to make the types of progressive changes called for by the feminist critique. In light of the deep roots
of gender bias in the history of medical science, and the bias which
continues to exist in society more generally, it does not seem reasonable
to expect that the research community will voluntarily dispose of its
89 NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical
Research, 59 FR 11146 at Ill.C.
90
Tri-Council Policy Statement, supra note 41 at Art. 5.2.
91 Supra note 20.
92 Medical Research Com1cil, Guidelines on Research Involving Human Subjects (Ottawa,
Ont.: Agency, 1987) at 11.
93 Supra note 20 at i.8.
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traditional exclusionary practices. Subsequently, as the government has
repeatedly expressed commitment to advancing women's health
through research, it seems that more meaningful action is required than
what has occurred thus far.

VI. CONCLUSION
The women's health movement has had some political success in
Canada. This is reflected in the establishment of a Women's Health
Bureau at Health Canada, funding for women-centred research programs, and the implementation of an inclusionary clinical trials policy in
the area of new drug submissions. At the same time, however, the extent
of conceivable social change within the existing regulatory framework
of law and ethics is very limited. Federal legislative intervention, which
would be consistent with the numerous international pledges made by
the Canadian government to advance the women's health agenda, may
prove to be the most viable route to facilitating substantive change at the
level where the bulk of research decision-making occurs. Intensive
public lobbying is needed to ensure Ottawa resists simply accepting the
agenda of the entrenched, deep-pocketed research community.

